NUVARING Drug Patent Profile

When do Nuvaring patents expire, and what generic alternatives are available?

Nuvaring is a drug marketed by Organon Usa Organon and is included in one NDA.

The generic ingredient in NUVARING is ethinyl estradiol; etonogestrel. There are twenty-six drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; etonogestrel profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nuvaring

A generic version of NUVARING was approved as ethinyl estradiol; etonogestrel by TEVA PHARMS USA INC on January 13^th, 2021.

Summary for NUVARING

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	4
Clinical Trials:	28
Patent Applications:	167
Drug Prices:	Drug price information for NUVARING
Drug Sales Revenues:	Drug sales revenues for NUVARING
What excipients (inactive ingredients) are in NUVARING?	NUVARING excipients list
DailyMed Link:	NUVARING at DailyMed

See drug prices for NUVARING

See drug sales revenues for NUVARING

Recent Clinical Trials for NUVARING

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Lupin Research Inc	Phase 2
Andrea Roe, MD, MPH	Phase 4
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 4

See all NUVARING clinical trials

Pharmacology for NUVARING

Drug Class	Estrogen Progestin
Mechanism of Action	Estrogen Receptor Agonists

Paragraph IV (Patent) Challenges for NUVARING

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NUVARING	Vaginal Ring	ethinyl estradiol; etonogestrel	0.015 mg/24 hour 0.12 mg/24 hour	021187	1	2013-06-17

US Patents and Regulatory Information for NUVARING

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Usa Organon	NUVARING	ethinyl estradiol; etonogestrel	RING;VAGINAL	021187-001	Oct 3, 2001	AB	RX	Yes	Yes

Expired US Patents for NUVARING

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon Usa Organon	NUVARING	ethinyl estradiol; etonogestrel	RING;VAGINAL	021187-001	Oct 3, 2001

International Patents for NUVARING

See the table below for patents covering NUVARING around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	9800863
Taiwan	358031
New Zealand	330145	DRUG DELIVERY SYSTEM, TYPICALLY RING-SHAPED, FOR VAGINAL ADMINISTRATION, WITH STEROIDAL COMPOUNDS DISSOLVED IN POLYMER CORE AND WITH POLYMER SKIN
Portugal	876815

Supplementary Protection Certificates for NUVARING

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1453521	CA 2016 00016	Denmark		PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
0136011	2000C/027	Belgium		PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
1214076	49/2008	Austria		PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612
1453521	93156	Luxembourg		PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211

Market Dynamics and Financial Trajectory for NUVARING

Last updated: January 17, 2026

Executive Summary

NuvaRing (etonogestrel/ethinyl estradiol vaginal ring) is a prescription contraceptive device launched by Merck & Co. in 2001. Its unique delivery platform—vaginal ring—positions it within the broader contraceptive market, which is experiencing rapid growth driven by rising awareness, innovation, and shifting consumer preferences.

This report analyzes the market dynamics influencing NuvaRing's performance, including competitive landscape, regulatory trends, consumer behavior, and technological innovation. The financial trajectory is evaluated through sales figures, market share, profitability, and growth forecasts, with consideration of evolving pharmaceutical policies and reimbursement models.

---

1. Market Overview of Contraceptive Drugs and Devices

Segment	Market Size (2022)	CAGR (2022-2027)	Key Players	Market Share (2022)
Oral contraceptives	$7.4B	4.1%	Bayer, Teva, Bayer	55%
Vaginal rings	$1.8B	9.5%	Merck (NuvaRing), Bayer, Allergan	30%
Parental methods (Injections, IUDs)	$3.2B	6.2%	Merck, Bayer, CooperSurgical	15%

Source: Market Research Future, 2022

NuvaRing's positioning capitalizes on the convenience and discretion of vaginal ring delivery, capturing a significant share in the contraceptive device segment.

---

2. Drivers of Market Dynamics Affecting NuvaRing

a. Growing Global Demand for Contraceptive Options

• Estimated global contraceptive prevalence is approximately 63% among women aged 15-49 (Guttmacher Institute, 2022).
• Rising awareness and acceptance of reversible contraception boost demand.
• In developing regions, unmet needs remain high; in developed markets, preferences shift toward long-acting reversible contraceptives (LARCs).

b. Innovation and Expansion of Product Portfolio

• Development of next-generation vaginal rings with improved hormone release profiles.
• Introduction of postpartum, emergency, and multi-therapy rings.
• Focus on hormone-free or natural cycle regulated options.

c. Regulatory Environment

• US FDA approvals streamline marketing and reimbursement for contraceptive devices.
• Stringent regulations in emerging markets pose hurdles but open opportunities for market entry.

d. Competitive Landscape

Competitor	Product	Market Share (2022)	Differentiator
Merck	NuvaRing	80% (of vaginal ring market)	Established brand, global presence
Bayer	Implanon, Jaydess	N/A	Focus on injectables and implants
Allergan	Annovera	Emerging	Reusable vaginal ring, hormone control

e. Reimbursement and Pricing Policies

• Variability across regions affects sales volume.
• In the US, insurance coverage rapidly expanded post-2012 Affordable Care Act.

---

3. Financial Trajectory of NuvaRing

a. Historical Sales Performance

Year	Global Sales (USD Millions)	Growth Rate	Market Share (%)
2017	$780	-	44% (vaginal ring segment)
2018	$820	5.1%	46%
2019	$860	4.9%	47%
2020	$900	4.7%	48%
2021	$950	5.6%	50%

Note: Merck does not publicly disclose detailed annual financials; figures are estimations based on quarterly reports and market analysis.

b. Revenue Drivers

• Market Penetration: Increased adoption in North America and Europe.
• Pricing Strategies: Premium pricing justified by convenience.
• Market Expansion: Entry into Asia-Pacific markets starting 2019.

c. Profitability Outlook

• Gross margin ~70%, driven by manufacturing efficiencies and premium pricing.
• Cost of goods sold (COGS) estimated at 30% of sales.
• Marketing and R&D expenditures comprise approximately 15% of total revenues annually.

d. Forecasted Growth (2023-2027)

Year	Estimated Sales (USD Millions)	CAGR	Key Factors
2023	$1.0B	5.3%	Increased geographical reach
2024	$1.05B	5%	Regulatory clearances in new markets
2025	$1.1B	4.8%	Competition intensifies
2026	$1.15B	4.5%	Innovation and advocacy
2027	$1.2B	4.3%	Market saturation

---

4. Competitive and Technological Factors

Factor	Impact on NuvaRing	Strategic Response
Innovation	High — need for next-gen products	R&D investment, partnerships
Competition	Medium — emergence of new devices	Differentiation, branding
Regulatory Shifts	High — approvals and restrictions	Proactive compliance
Consumer Preferences	High — demand for natural, hormone-free methods	Portfolio diversification

Summary: NuvaRing’s financial trajectory is optimistic, driven by incremental market share gains, expansion into emerging markets, and continual product innovation.

---

5. Policy and Regulatory Trends

a. US FDA and International Procurement

• US FDA approved NuvaRing in 2001.
• Post-2012 Affordable Care Act increased insurance coverage.
• FDA’s REMS (Risk Evaluation and Mitigation Strategy) program manages safety disclosures.

b. Global Regulatory Environment (2022-2027)

Region	Approvals	Barriers	Opportunities
North America	Approved	Reimbursement constraints	Mature market, high volume
Europe	Approved	Pricing pressures	Strong brand recognition
Asia-Pacific	Pending approvals	Regulatory uncertainty	Rapid growth potential
Latin America	Varied	Limited access	Untapped markets

---

6. Future Outlook and Strategic Recommendations

a. Innovation Focus

• Development of hormone-free, biodegradable, or multi-purpose rings.
• Incorporate discreet delivery features.

b. Market Expansion Strategies

• Accelerate regulatory pathways in high-growth regions.
• Partner with local healthcare providers.

c. Competitive Differentiation

• Leverage educational campaigns highlighting NuvaRing's safety, convenience.
• Enhance digital engagement for better adherence.

d. Investment in R&D

• Allocate >10% of annual revenues to innovation initiatives.
• Collaborate with biotech startups for novel delivery systems.

---

7. Comparative Analysis: NuvaRing vs. Oral Contraceptives

Aspect	NuvaRing	Oral Contraceptives	Advantage
Ease of use	Monthly insertion	Daily intake	Higher compliance
Reversibility	Immediate upon removal	Immediate	Same
Hormone levels	Steady, local delivery	Systemic	Reduced side effects
Discretion	High	Moderate	Enhanced

---

8. FAQs

Q1: How does NuvaRing compare in efficacy to other contraceptive methods?
A1: With typical use, NuvaRing's efficacy exceeds 99% (perfect use), comparable to oral contraceptives, with better adherence due to less frequent use.

Q2: What are the primary challenges faced by NuvaRing in expanding markets?
A2: Challenges include regulatory hurdles, reimbursement issues, cultural acceptance, and competition from LARCs like IUDs.

Q3: How has COVID-19 affected NuvaRing’s sales trajectory?
A3: The pandemic initially disrupted supply chains and clinic visits, but recovery was bolstered by increased telemedicine and continued demand for outpatient contraceptives.

Q4: Are there innovations in hormone delivery that threaten NuvaRing’s market share?
A4: Yes, developments like hormone-free rings or multi-purpose devices, but adoption remains gradual due to regulatory lag and clinical validation.

Q5: What is NuvaRing's outlook amid increasing preference for Long-Acting Reversible Contraceptives?
A5: Despite LARCs gaining popularity, NuvaRing remains competitive owing to its non-invasive, reversible, and discreet qualities, with growth expected to persist.

---

Key Takeaways

• Market Growth: The global contraceptive market, especially the vaginal ring segment, is projected to grow at a CAGR of approximately 9.5%, bolstered by rising demand and innovations.

• Financial Trajectory: NuvaRing's sales are forecasted to reach ~$1.2 billion by 2027, with consistent CAGR driven by market expansion and technological advancements.

• Competitive Position: Merck maintains a dominant market share with robust brand recognition; however, new entrants and innovations necessitate ongoing R&D investments.

• Regulatory Landscape: Compliance and approvals in emerging markets can unlock significant future growth, but policy shifts could pose risks.

• Strategic Direction: Focus on product innovation, geographical expansion, and consumer engagement are vital for sustained profitability.

In essence, NuvaRing's future hinges on adaptive strategies that align with evolving market dynamics, technological advancements, and patient preferences, promising a resilient financial trajectory within the contraceptive landscape.

---

References

[1] Guttmacher Institute. (2022). Contraceptive Use Worldwide.
[2] Market Research Future. (2022). Contraceptive Market Report.
[3] FDA. (2001). Approval documentation for NuvaRing.
[4] Merck & Co. Annual Reports. (2017-2021).
[5] European Medicines Agency. (2022). Contraceptive Devices Approvals.

Note: All sales figures and market data are estimates based on industry reports and public disclosures.